Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Disease Cell Type Therapeutic or Technology Institution Stage Project Objectivesort ascending Details
Brain Cancer,
Neurological Disorders
Embryonic Stem Cell Exosomes based therapy UC Irvine
Development Candidate, Proof of Concept
Spinal Cord Injury Embryonic Stem Cell Gene-modified, donor cell therapy UCSD
Development Candidate, Research Insights
Anemia Adult Stem Cell,
iPS Cell
Small molecule therapy Stanford
Development Candidate, Proof of Concept
Traumatic Brain Injury Embryonic Stem Cell Exosomes based therapy UC Irvine
Development Candidate, Proof of Concept, Research Insights
Heart failure iPS Cell Exosomes based therapy Stanford
Development Candidate, Proof of Concept
Angelman Syndrome,
Autism
iPS Cell Gene Therapy, cell free UC Davis
Development Candidate, Proof of Concept
Epidermolysis Bullosa iPS Cell Gene-modified, personalized cell therapy Stanford
Development Candidate, Proof of Concept
Ovarian Cancer iPS Cell Gene-modified, donor cell therapy UCSD
Development Candidate, Proof of Concept
Ovarian Cancer iPS Cell Gene-modified, donor cell therapy UCSD
Development Candidate, Proof of Concept
Amyotrophic Lateral Sclerosis Adult Stem Cell Donor cell therapy UCSD
Development Candidate, Proof of Concept
COVID-19,
Respiratory Disorders
iPS Cell Small molecule therapy UCLA
Development Candidate, Proof of Concept
Blood Disorders Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Development Candidate, Proof of Concept
Heart Disease iPS Cell Model system development Stanford
Development Candidate, Proof of Concept
Brain Cancer Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Development Candidate, Proof of Concept
Type 1 diabetes Embryonic Stem Cell Gene-modified, donor cell therapy Lundquist Institute
Development Candidate, Proof of Concept
Ovarian Cancer Adult Stem Cell Gene-modified, personalized cell therapy COH
Development Candidate, Proof of Concept
Inflammatory bowel disease Adult Stem Cell Donor cell therapy Vitabolus, Inc.
Development Candidate, Proof of Concept
Heart Disease,
Danon Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSD
Development Candidate, Proof of Concept
Neurological Disorders Embryonic Stem Cell Donor cell therapy UC Irvine
Development Candidate, Proof of Concept
Dementia iPS Cell Donor cell therapy Gladstone
Development Candidate, Proof of Concept
Amyotrophic Lateral Sclerosis iPS Cell Nucleic acid based therapy USC
Development Candidate, Proof of Concept
Vision Loss iPS Cell Small molecule therapy UCSD
Development Candidate, Proof of Concept
COVID-19 Adult Stem Cell Vaccine UCLA
Development Candidate, Proof of Concept
Traumatic Brain Injury iPS Cell Donor cell therapy UC Irvine
Development Candidate, Research Insights
Hemophilia A Adult Stem Cell Gene modification COH
Development Candidate, Proof of Concept
Liver Disease iPS Cell Gene-modified, donor cell therapy CHLA
Development Candidate, Proof of Concept
Stroke iPS Cell Donor cell therapy UCLA
Development Candidate, Proof of Concept
Heart Disease iPS Cell Donor cell therapy UC Davis
Development Candidate, Proof of Concept
Hearing Loss Adult Stem Cell Protein/peptide therapy Stanford
Development Candidate, Proof of Concept
Amyotrophic Lateral Sclerosis Adult Stem Cell Personalized cell therapy BrainStorm
Clinical Trial, Phase 3
Kidney Failure Adult Stem Cell Donor cell therapy Medeor Therapeutics
Clinical Trial, Phase 3
Retinitis Pigmentosa Therapeutic Approach jCyte
Clinical Trial, Phase 2
Sickle Cell Disease Adult Stem Cell Gene-modified, personalized cell therapy Boston Children's Hospital
Clinical Trial, Phase 2
Immune Disease,
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy Orchard Therapeutics
Clinical Trial, Phase 2
COVID-19 Adult Stem Cell Donor cell therapy UCSF
Clinical Trial, Phase 2
Retinitis Pigmentosa Other Donor cell therapy jCyte
Clinical Trial, Phase 2
Sickle Cell Disease Adult Stem Cell Donor cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2
Amyotrophic Lateral Sclerosis Adult Stem Cell Gene-modified, donor cell therapy Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
Retinitis Pigmentosa Adult Stem Cell Donor cell therapy Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Immune Disease,
Severe Combined Immunodeficiency, X-linked (X-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy St. Jude
Clinical Trial, Phase 1 or Phase 1/2
B cell cancers,
Leukemia
Adult Stem Cell Gene-modified, personalized cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage Adult Stem Cell Personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, X-linked (X-SCID) Adult Stem Cell Antibody Jasper Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Alpha Thalassemia Major Adult Stem Cell Donor cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
Parkinson's Disease Vital Research Opportunity Gene Therapy, cell free Brain Neurotherapy Bio
Clinical Trial, Phase 1 or Phase 1/2
Lung Cancer Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Kidney Failure Adult Stem Cell Donor cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
Osteonecrosis Adult Stem Cell Small molecule therapy UC Davis
Clinical Trial, Phase 1 or Phase 1/2

Pages

Icon for csv export